Nebenwirkungen · Tepadina
TEPADINA 200 mg powder and solvent for solution for infusion TEPADINA 400 mg powder and solvent for solution for infusion · Abschnitt 4.8 · PDF-Seite 30
HOS-210445 · Präparat HOS-154509
Skin and subcutaneous tissue Rash Severe toxic skin disorders Erythema reactions including Desquamation cases of Stevens- Pigmentation Johnson syndrome disorder and toxic epidermal necrolysis Musculoskeletal and connective Growth tissue disorders retardation Renal and urinary disorders Bladder disorders Renal failure Cystitis haemorrhagic General disorders and Pyrexia administration site conditions Mucosal inflammation Pain Multi-organ failure Investigations Blood bilirubin Blood urea increased increased Transaminases Blood electrolytes increased abnormal Blood creatinine Prothrombin time increased ratio increased Aspartate aminotransferase increased Alanine aminotransferase increased
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-24T14:00:00Z · SHA-256 42c8bab87a55159cb982d55f577a064273549ce149f75b75dbf4d5650be413bc · Passage 2ceb555c2f9e9a8dab5571c6cf9e14d9b37cfa341a613022465af2f300067176 · Zeichen 11645–13480 im Abschnitt